Exciting ESMO 2025 Highlights from Akeso
Akeso Inc. (9926.HK) is thrilled to share significant advancements in cancer treatment as they prepare for the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Congress. An important part of this event will be the Late-Breaking Abstract (LBA) featuring results from the Phase III clinical study of ivonescimab—a first-in-class bispecific antibody that targets PD-1 and VEGF. This study will showcase the treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) in a comparison against tislelizumab, another established therapy.
Key Presentation on Ivonescimab
The HARMONi-6 trial, led by the esteemed Professor Lu Shun from Shanghai Chest Hospital, will highlight compelling findings about ivonescimab in combination with chemotherapy. This study’s inclusion in the prestigious Presidential Symposium at ESMO reflects its significance in the scientific community. Presenting on a prestigious stage like this underscores the study's importance in paving the way for future treatment options in oncology.
What to Expect from the HARMONi-6 Study
During the presentation, attendees can anticipate in-depth insights into the efficacy and safety of ivonescimab. Data from this study will detail how the combination therapy improves patient outcomes, especially in maximizing progression-free survival (PFS). Importantly, these outcomes demonstrate ivonescimab’s transformative potential over first-generation immuno-oncology treatments, marking it as a pivotal step forward in cancer care.
Cadonilimab's Role in Advanced Gastric Cancer
In addition to ivonescimab, Akeso will also present results from the Phase III COMPASSION-15 clinical trial, which evaluates cadonilimab—another groundbreaking bispecific antibody targeting PD-1 and CTLA-4. Professor Shen Lin from Peking University Cancer Hospital will share the compelling data from this study on the treatment of unresectable gastric cancer. This presentation will be part of a Mini Oral Session at ESMO.
Impact of Cadonilimab in Clinical Practice
The COMPASSION-15 study's findings will reinforce cadonilimab's status as a transformative option in treating advanced gastric adenocarcinoma. With successful approval by regulatory agencies earlier this year, the drug's emerging data reflects its promising capabilities and the changing landscape of gastric cancer treatment. The inclusion of cadonilimab in the 2025 CSCO Gastric Cancer Guidelines further cements its position as a leading therapy and paves the way for better outcomes for patients worldwide.
Looking Forward: Akeso's Vision
Akeso's focus extends beyond these specific studies. The company is clearly dedicated to expanding their innovative pipeline. As they explore therapies for various disease states, their commitment to bridging the gap between traditional and novel treatment strategies remains a priority. This includes advancing treatment methodologies that not only improve health outcomes but also provide accessible medicine globally.
Frequently Asked Questions
What are the highlights of Akeso's presentations at ESMO 2025?
Akeso will showcase pivotal findings from the HARMONi-6 study on ivonescimab and the COMPASSION-15 trial on cadonilimab, indicating promising advancements in cancer treatment.
What is ivonescimab, and why is it significant?
Ivonescimab is a novel bispecific antibody targeting PD-1 and VEGF, promising to improve treatment strategies for advanced sq-NSCLC compared to existing therapies.
Who will present the studies at the conference?
Professor Lu Shun will present the HARMONi-6 results, while Professor Shen Lin will discuss findings from the COMPASSION-15 trial.
How does cadonilimab compare to other treatments?
Cadonilimab has shown transformative potential in treating advanced gastric cancer, outperforming many existing therapies and is recognized in national guidelines.
What is Akeso's overarching goal in cancer treatment?
Akeso aims to develop first-in-class therapies and enhance treatment efficacy across various cancers while ensuring global access to innovative medicines.
